Minerva Neurosciences, Inc. — FY2021 Form 10-K
Business context and reporting period. This clinical-stage biopharmaceutical company reported for the fiscal year ended December 31, 2021. Its lead candidate, roluperidone, is being developed for negative symptoms of schizophrenia; MIN-301 is intended for Parkinson’s disease. The company has no approved products and generated no product-sale revenue.
Key financial metrics
| Metric | FY2021 | FY2020 |
|---|---|---|
| Revenue | $0 | $41.2 million collaborative revenue |
| Research and development expense | $32.0 million | $22.0 million |
| General and administrative expense | $13.3 million | $17.3 million |
| Operating loss (income) | ($45.4 million) | $1.8 million income |
| Net loss (income) | ($49.9 million), or ($1.17) per share | $1.9 million, or $0.05 per share |
| Net cash used in operations | $24.6 million | $33.8 million |
| Cash, cash equivalents and restricted cash at year-end | $60.9 million | $25.5 million |
For Q4 2021, GAAP net loss was $21.3 million, versus $7.3 million in Q4 2020. Management’s non-GAAP net loss was $5.0 million ($0.12 per share), versus $5.3 million ($0.12 per share), respectively. Non-GAAP adjustments included impairment, royalty-sale interest, stock compensation, and— for FY2020—collaborative revenue; the measure is not directly comparable across companies.
At December 31, 2021, total assets were $77.1 million, total liabilities $69.1 million, and stockholders’ equity $8.0 million. Current assets were $62.2 million and current liabilities $2.8 million. The $66.3 million liability related to the sale of future royalties is debt-like financing, not revenue; the filing reports no conventional term-loan balance. No operating cash-flow margin is meaningful because the company had no FY2021 revenue.
Material changes versus FY2020
- FY2020 revenue of $41.2 million arose from the one-time recognition of deferred Janssen collaboration revenue after Minerva opted out of the seltorexant agreement; there was no comparable revenue in 2021.
- FY2021 R&D expense increased by $10.0 million, principally because of a $15.2 million non-cash MIN-301 impairment, partly offset by lower clinical and stock-compensation costs. Direct roluperidone development costs declined to $14.4 million from $18.0 million.
- Minerva received $60 million upfront from Royalty Pharma in January 2021 for its seltorexant royalty rights. The transaction was accounted for as a financing liability; Minerva recorded $6.3 million of non-cash interest expense in 2021. Up to $95 million of additional payments depend on clinical, regulatory and commercial milestones.
- Operating cash use fell by $9.2 million year over year, while cash increased by $35.4 million, largely reflecting the $60 million royalty-sale proceeds. The company did not sell shares under its at-the-market program in 2021.
Outlook, commentary and risks
- Management said existing cash was expected to cover commitments for at least 12 months after issuance of the financial statements, while also stating that additional capital will be needed to fund operations and later-stage development. Future funding availability and terms are uncertain; equity financing could dilute shareholders.
- Minerva continued preparing for a potential roluperidone NDA submission in the first half of 2022, subject to FDA meeting timing and feedback. The FDA denied a requested pre-NDA meeting and indicated a Type C meeting was more appropriate. The filing does not report the outcome of that subsequent meeting.
- Roluperidone’s 2020 Phase 3 trial missed its primary endpoint and key secondary endpoint in the intent-to-treat population. The 64 mg dose showed nominal statistical separation on the secondary endpoint, and an analysis excluding 17 patients from one site produced a nominal primary-endpoint p-value of 0.044. FDA previously cautioned that an NDA based on the existing studies was highly unlikely to be filed and raised substantial evidence concerns; it said site exclusion would require justification and results with and without those data. Management believes the data package and bioequivalence work support continued development, but approval and filing are uncertain.
- The 40-week roluperidone open-label extension reported symptom and functional-score improvements, but was not placebo-controlled; 202 of 333 participants completed it. The filing describes treatment as generally tolerated, while noting serious adverse events, discontinuations, transient QT prolongations and one treatment-unrelated death after treatment discontinuation.
- MIN-301 development was deferred because of limited resources, and its $15.2 million in-process R&D asset was fully impaired to zero. Management said development could resume if resources become available.
- Key risks include clinical and regulatory failure or delay, capital needs, dependence on contract manufacturers and research organizations, competition, reimbursement and pricing uncertainty, COVID-19 disruption, and intellectual-property and collaboration risks. Royalty Pharma’s future milestone payments depend on Janssen’s progress; Minerva also disclosed potential payment exposure if Janssen breaches certain royalty obligations.
- Two putative securities class actions concerning roluperidone disclosures were voluntarily dismissed, and the court closed the consolidated case in July 2021. The filing reports no pending income-tax examinations or subsequent events.
Important facts for investors to verify
- FDA feedback and the evidentiary requirements for filing and approval of a roluperidone NDA, including treatment of the 17-patient site exclusion and the Phase 3 ITT results.
- Actual cash runway against clinical, regulatory and potential commercialization spending, and the timing and terms of any additional financing.
- Royalty-sale liability assumptions, the effective interest rate (estimated at 10.7% at year-end), and conditions for any additional Royalty Pharma milestone payments.
- Whether MIN-301 development resumes and whether its impairment assumptions or carrying value change.
- Progress of Janssen’s seltorexant Phase 3 program and any resulting milestone obligations or receipts under the royalty-sale agreement.